Has Erika Hamilton, MD received payments from drug or device companies?

Yes. Drug and device makers reported $178,657 in general payments to Erika Hamilton, MD across 467 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Erika Hamilton, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Erika Hamilton, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Erika Hamilton, MD

Hematology & Oncology · Nashville, TNNPI 1902007107

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $111,040 of the $178,657 with a category attached, or 62.2%. 60 manufacturers reported payments, led by Daiichi Sankyo Company LTD at 26.0% of the total. Among hematology & oncology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$178,657in general payments, 2019–2025

Across 467 payments — averaging $382.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Company LTD$46K
Daiichi Sankyo Inc.$25K
E.r. Squibb & Sons, L.L.C.$16K
Pfizer$15K
Novartis$15K
F. Hoffmann-la Roche AG$13K
plus $48K from 54 others

$45,330,207in research payments, 2019–2025

Across 6,423 payments — averaging $7057.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$9M
Pfizer$6.6M
Seagen Inc.$5.2M
Genentech, Inc.$3.7M
Novartis$2.4M
Daiichi Sankyo Inc.$2M
plus $16.4M from 41 others

What the payments were for

Consulting fees$111,04062%
Speaking & faculty fees$21,60512%
Travel & lodging$34,55919%
Food & beverage$11,4226%
Education$310%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Company LTD	8	$46,438
Daiichi Sankyo Inc.	44	$24,731
E.r. Squibb & Sons, L.L.C.	28	$16,393
Pfizer	46	$15,433
Novartis	26	$14,778
F. Hoffmann-la Roche AG	9	$12,754
Seagen Inc.	17	$11,177
Lilly USA, LLC	10	$7,770
Stemline Therapeutics Inc.	9	$6,026
Gilead(2 entities)	19	$4,897
Eli Lilly	25	$3,396
Deciphera Pharmaceuticals Inc.	2	$3,022
Merck	18	$2,889
Janssen Research & Development, LLC	1	$2,600
AstraZeneca(2 entities)	33	$1,145
Astrazeneca UK Limited	17	$977
Beigene USA, Inc.	6	$889
Regeneron Healthcare Solutions, Inc.	15	$394
Genentech USA, Inc.	13	$368
Jazz Pharmaceuticals Inc.	4	$365
Eisai Inc.	14	$290
Johnson & Johnson	8	$139
EMD Serono, Inc.	7	$116
Array Biopharma Inc	6	$111
Bayer	6	$100
Sanofi	4	$83
Tersera Therapeutics LLC	4	$77
Genmab U.S., Inc.	3	$71
Bristol Myers Squibb	3	$67
Tempus AI, Inc	3	$67
Lexicon Pharmaceuticals, Inc.	5	$65
Exelixis Inc.	3	$57
Sun Pharmaceutical Industries Inc.	3	$56
Coherus Oncology, Inc.	3	$49
Amgen	3	$47
Astellas Pharma US Inc	2	$46
AbbVie	2	$45
AVEO Pharmaceuticals, Inc.	2	$45
GSK	2	$44
Pharmacyclics LLC, An Abbvie Company	2	$42
Boehringer Ingelheim	2	$38
Clovis Oncology, Inc.	3	$37
Servier Pharmaceuticals LLC	2	$36
Recordati_rare_diseases_inc.	1	$33
Blueprint Medicines Corporation	1	$32
Rigel Pharmaceuticals, Inc.	2	$31
Taiho Oncology, Inc.	2	$30
Legend Biotech USA Inc.	1	$25
Beone Medicines USA, Inc.	1	$25
Springworks Therapeutics, Inc.	1	$22
Incyte Corporation	1	$22
Novo Nordisk	1	$22
Verity Pharmaceuticals Inc.	1	$21
Avyxa Pharma, LLC	1	$21
Karyopharm Therapeutics Inc.	1	$21
Invivyd Inc	1	$20
Ipsen Biopharmaceuticals, Inc	1	$18
Agios Pharmaceuticals, Inc.	1	$18
Caris MPI, Inc.	1	$17
Mirati Therapeutics, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Enhertu$53,529
KISQALI$11,290
Perjeta$7,810
TECENTRIQ$5,960
TUKYSA$4,950
Kadcyla$4,940
IBRANCE$4,906
Orserdu$2,820
KEYTRUDA$2,500
PIQRAY$2,350
Herceptin$1,140
ZIIHERA$265
Trodelvy$222

How this compares

$178,657 in reported general payments places this provider in the 90th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$1,031,539

Medicare patients

198

Services billed

34,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Letrozole	67	$1,608
Tamoxifen Citrate	30	$857
Potassium Chloride	12	$127

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Nashville

Jonathan AbbasNashville$1.3M
Alan TanNashville$1.1M
Kent ShihNashville$900K
Brian RiniNashville$601K
Wade IamsNashville$601K
Krish PatelNashville$531K
Sandeep RajanNashville$465K
Todd BauerNashville$357K
Muhamed BaljevicNashville$313K
Olalekan OluwoleNashville$311K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →